Back to home

    Injective

    INJ

    @InjectiveLabs

    Evaluation Score

    Overall rating on a scale of 0-10

    RiskReturn
    07.110
    Risk Level:
    Medium
    Recommendation:Buy
    Evaluated:August 27, 2026 (v14)

    Dimension Breakdown

    Development Activity8.5
    Community Health7.0
    Tokenomics7.5
    Market & Use Case6.8
    Team & Governance7.5
    Security & Audits4.5

    AI Analysis

    Comprehensive evaluation of the token

    Injective (INJ) demonstrates strong technical momentum and ecosystem maturity, highlighted by active development (8.5/10) with continuous mainnet upgrades and dynamic EVM scaling throughout 2026. The tokenomics model (7.5/10) features a 100% circulating supply, staking utility, and an active deflationary burn auction mechanism. Team, governance, and community support remain robust (7.5/10 and 7.0/10 respectively), supported by reputable institutional backing and an established decentralized governance process. Market positioning (6.8/10) is solid with deep liquidity across tier-1 venues, though tempered by severe market drawdown from all-time highs and fierce competition in decentralized derivatives. The primary area of concern lies in Security and Audit History (4.5/10), driven by a July 2026 supply-chain compromise of Injective Labs' GitHub repository that published backdoored TypeScript SDK packages targeting wallet private keys. While formal protocol-level audits by Informal Systems verify core exchange modules and no specific aggregate loss figure met the threshold for a protocol-level red-flag score cap, the operational security breach introduces material risk that lowers the overall rating.

    Development Activity

    Code updates and developer engagement

    RiskReturn
    08.510

    Community Support

    Social media presence and community engagement

    RiskReturn
    07.010

    Tokenomics

    Supply, distribution, and utility

    RiskReturn
    07.510

    Market & Use Case

    Value proposition and competitive landscape

    RiskReturn
    06.810

    Team & Governance

    Team background and project governance

    RiskReturn
    07.510

    Security & Audits

    Security history and audit status

    RiskReturn
    04.510

    About Injective (INJ)

    Injective (INJ) is the native utility, staking, and governance token of Injective, a Cosmos SDK-based Layer-1 blockchain built specifically for financial applications. Co-founded by Eric Chen and Albert Chon and backed by institutional investors including Pantera Capital, Jump Crypto, and Brevan Howard, the network operates using Tendermint Proof-of-Stake consensus and features an on-chain order book, dynamic EVM architecture scaling, and cross-chain interoperability. INJ also exists as an ERC-20 token on the Ethereum blockchain and is used for network fee settlement, protocol governance voting, derivatives collateral, and validator staking.

    The INJ token launched in October 2020 with an initial fixed supply of 100 million tokens. According to project data, the token has reached 100% circulation with no remaining scheduled token unlocks. The tokenomics model incorporates deflationary features, including weekly buy-back-and-burn auctions, dynamic mint modules, and community-approved protocol changes such as the January 2026 IIP-617 proposal designed to increase burn rates. Ecosystem applications built on the chain include the decentralized exchange Helix, which has handled significant cumulative trading volume.

    Injective's core exchange, oracle, and insurance modules have undergone security reviews by Informal Systems. However, the project has experienced material security and market challenges. In July 2026, Injective Labs' GitHub distribution infrastructure suffered a supply-chain compromise in which a backdoored TypeScript SDK update was published to npm to capture wallet private keys and seed phrases from developers and end-users, though no aggregate loss amount was officially confirmed. Additionally, INJ has experienced substantial market drawdown, trading approximately 91% below its all-time high of $52.62, while facing governance centralization considerations around Injective Labs and strong competition within the decentralized derivatives market.

    Similar Rated Tokens